1. Home
  2. AKAN vs PRFX Comparison

AKAN vs PRFX Comparison

Compare AKAN & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akanda Corp.

AKAN

Akanda Corp.

SELL

Current Price

$2.76

Market Cap

1.4M

Sector

Health Care

ML Signal

SELL

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$2.55

Market Cap

1.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKAN
PRFX
Founded
2021
2007
Country
Canada
Israel
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4M
1.6M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
AKAN
PRFX
Price
$2.76
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
123.6K
344.5K
Earning Date
04-29-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.58
52 Week High
$9.29
$3.71

Technical Indicators

Market Signals
Indicator
AKAN
PRFX
Relative Strength Index (RSI) 87.65 56.63
Support Level $0.85 $1.28
Resistance Level $3.40 $2.91
Average True Range (ATR) 0.11 0.30
MACD 0.15 0.05
Stochastic Oscillator 88.56 75.08

Price Performance

Historical Comparison
AKAN
PRFX

About AKAN Akanda Corp.

Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.

Share on Social Networks: